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RESEARCH ARTICLE Open Access
Activated thrombin-activatable fibrinolysis
inhibitor (TAFIa) attenuates breast cancer
cell metastatic behaviors through inhibition
of plasminogen activation and extracellular
proteolysis
Zainab A. Bazzi1, Danielle Lanoue1, Mouhanned El-Youssef1, Rocco Romagnuolo1, Janice Tubman2,
Dora Cavallo-Medved2, Lisa A. Porter2 and Michael B. Boffa1*
Abstract
Background: Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen, which can be converted to
activated TAFI (TAFIa) through proteolytic cleavage by thrombin, plasmin, and most effectively thrombin in complex
with the endothelial cofactor thrombomodulin (TM). TAFIa is a carboxypeptidase that cleaves carboxyl terminal
lysine and arginine residues from protein and peptide substrates, including plasminogen-binding sites on cell
surface receptors. Carboxyl terminal lysine residues play a pivotal role in enhancing cell surface plasminogen
activation to plasmin. Plasmin has many critical functions including cleaving components of the extracellular matrix
(ECM), which enhances invasion and migration of cancer cells. We therefore hypothesized that TAFIa could act to
attenuate metastasis.
Methods: To assess the role of TAFIa in breast cancer metastasis, in vitro migration and invasion assays, live cell
proteolysis and cell proliferation using MDA-MB-231 and SUM149 cells were carried out in the presence of a TAFIa
inhibitor, recombinant TAFI variants, or soluble TM.
Results: Inhibition of TAFIa with potato tuber carboxypeptidase inhibitor increased cell invasion, migration and
proteolysis of both cell lines, whereas addition of TM resulted in a decrease in all these parameters. A stable variant
of TAFIa, TAFIa-CIIYQ, showed enhanced inhibitory effects on cell invasion, migration and proteolysis. Furthermore,
pericellular plasminogen activation was significantly decreased on the surface of MDA-MB-231 and SUM149 cells
following treatment with various concentrations of TAFIa.
Conclusions: Taken together, these results indicate a vital role for TAFIa in regulating pericellular plasminogen
activation and ultimately ECM proteolysis in the breast cancer microenvironment. Enhancement of TAFI activation
in this microenvironment may be a therapeutic strategy to inhibit invasion and prevent metastasis of breast cancer
cells.
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Background
Metastasis is the process by which malignant cells mi-
grate from the site of the primary tumor to distant parts
of the body [1]. This phenomenon is responsible for the
majority of breast cancer related deaths. The breast
tumor microenvironment facilitates metastasis by pro-
viding the necessary factors (such as stromal cells, sig-
naling molecules, and proteolytic enzymes) to initiate
the metastatic process. Importantly, metastasis is medi-
ated by the interaction between the tumor cells, stromal
cells and the extracellular matrix (ECM) [2, 3]. Proteins
in the tumor microenvironment influence the progres-
sion of cancer by providing a favourable environment
for ECM degradation. Specifically, the presence of prote-
ases such as plasmin and matrix metalloproteinases
(MMPs) mediate extracellular proteolysis, resulting in
ECM degradation [4, 5]. Degradation of the ECM pro-
motes cell migration and invasion and also releases la-
tent growth factors that stimulate cell proliferation [1].
The plasminogen activation system (PAS) plays a vital
role in extracellular proteolysis. Plasminogen is a zymo-
gen that is converted to its active form plasmin by uro-
kinase plasminogen activator (uPA) and tissue-type
plasminogen activator (tPA) [4], with uPA playing the
more important role in pericellular plasminogen activa-
tion [6]. Plasmin is a serine protease of broad specificity
that cleaves multiple substrates, including ECM proteins,
latent growth factors and a number of pro-MMPs [4].
Plasmin therefore is considered a pro-metastasis enzyme
[7]. The PAS is active in many types of cancers, includ-
ing breast cancer [4]. Specifically, uPA and its receptor,
urokinase plasminogen activator receptor (uPAR) are
expressed in tumor cells, as well as tumor-associated
stromal cells [4, 8]. Developing methods to target the
PAS could be key in inhibiting cancer cell invasion and
metastasis [9].
Thrombin activatable fibrinolysis inhibitor (TAFI), also
known as carboxypeptidase B, U or R [10], is a plasma
zymogen expressed mainly in the liver but also found in
megakaryocytes (leading to a platelet pool of TAFI) and
macrophages [11]. TAFI is converted to activated TAFI
(TAFIa) by proteolytic cleavage at Arg92 either by
thrombin, plasmin or thrombin in complex with the
endothelial cofactor thrombomodulin (TM). TAFIa is a
basic carboxypeptidase, which removes carboxyl-
terminal arginine and lysine residues from peptide
and protein substrates, including fibrin degradation
products (FDPs), anaphylatoxins C3a and C5a,
thrombin-cleaved osteopontin and cell-surface plas-
minogen receptors [12–15].
Intriguingly, TAFIa is intrinsically unstable, with a
half-life of 8–15 min at 37°C. This instability is consid-
ered to be the physiological means of TAFIa inhibition,
as no endogenous inhibitors exist [16]. Ceresa et al.
characterized a mutant of TAFIa with a 180-fold en-
hancement in half-life compared to wildtype TAFIa [17].
This stable mutant of TAFIa contains five point muta-
tions in the instability region, specifically S305C, T325I,
T329I, H333Y, H335Q and is therefore named TAFI-
CIIYQ.
The ability of TAFIa to cleave cell-surface plasminogen
receptors raises the possibility that TAFIa could modu-
late the PAS in the tumor microenvironment, thereby at-
tenuating the metastatic potential of the tumor cells.
Furthermore, TM, the cofactor necessary for physio-
logical activation of TAFI has been characterized as an
anti-metastatic factor. In vitro studies have shown that
TM can inhibit invasion of fibrosarcoma cells through
activation of TAFI [18]. An important in vivo study
demonstrated that the anti-metastatic potential of TM
could be attributed to its thrombin-binding domain [19].
In addition, expression of TM in breast cancer tumors is
inversely correlated to malignancy [20]. Therefore, we
hypothesized that the anti-metastatic potential of TM
may be mediated by its ability to enhance the activation
of TAFI. Here, we address this hypothesis using an in
vitro model of the breast tumor microenvironment.
Methods
Cell culture
MDA-MB-231 and HTB-126 cells (ATCC) were grown
in Dulbecco’s modified eagle medium (DMEM/F12)
(Invitrogen), containing 10 % fetal bovine serum (FBS)
and 1 % antibiotic-antimycotic (10 units/mL penicillin G
sodium, 10 μg/mL streptomycin sulfate and 25 ng/mL
amphotericin B) (Invitrogen). SUM149 cells (a kind gift
from Dr. Stephen Ethier, Karmanos Cancer Institute)
were cultured in DMEM/F12 containing 5 % FBS, 1 %
antibiotic-antimycotic, 10 μg/mL insulin (Sigma) and
0.5 μg/mL hydrocortisone (Sigma). MCF7 cells (ATCC)
were grown in RPMI-1640 medium (Gibco) containing
10 % FBS and 1 % antibiotic-antimycotic. MCF10A
(ATCC) and MCF10CA1a (obtained from the Karmanos
Biobanking and Correlative Sciences Core) were main-
tained in DMEM-F12 media containing 0.5 μg/ml
hydrocortisone, 10 μg/ml insulin, 20 ng/ml human EGF
and 5 % (vol/vol) heat inactivated horse serum. Human
embryonic kidney (HEK293) cells (ATCC) were cultured
in minimum essential medium (MEM) (Gibco) supple-
mented with 5 % FBS and 1 % antibiotic-antimycotic.
THP-1 acute monocytic leukemia cells (ATCC) were
cultured in RPMI-1640 medium adjusted to contain
4.5 g/L glucose, 10 mM HEPES pH 7.4 and 1.0 mM so-
dium pyruvate, and supplemented with 10 % (v/v) fetal
bovine serum (ATCC), 1 % (v/v) antibiotic-antimycotic,
and 50 μM β-mercaptoethanol. THP-1 monocytes were
differentiated by the addition of 100 nM phorbol 12-
myristate 13-acetate to the medium for 72 h. Human
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umbilical vein endothelial cells (HUVECs) (Lonza) were
grown in EGM Complete Medium (Lonza). All cells
were sub-cultured in 100 mm cell culture plates and
were kept in an incubator maintaining conditions of 37 °
C, 5 % CO2.
Cloning, expression and purification of recombinant TAFI
The full-length TAFI-CIIYQ cDNA sequence [17]
present in the pNUT vector [21] was used as a template
for PCR amplification. To insert TAFI-CIIYQ in the
pcDNA4A vector, unique PstI and AgeI restriction sites
were engineered at the 5′ and 3′ ends of the sequence
through PCR. PCR amplification was performed with
Phusion HF DNA polymerase (New England Biolabs) as
per manufacturer’s protocol, using TAFI-CIIYQ-pNUT
as the template (10 ng/μL) and the following primer
pair: sense 5′-AAA CTG CAG TTG GGA TGA AGC
TTT GC-3′ and anti-sense 5′-GGA CCG GTA ACA
TTC CTA ATG ACA TGC CAA G-3′. Using PstI and
AgeI, TAFI-CIIYQ cDNA was ligated into the pcDNA4A
plasmid in-frame with a carboxyl-terminal His6-tag-en-
coding sequence. TAFI-WT [21] was cloned into
pcDNA4A using the same method.
HEK293 cells were seeded into a 6-well plate at a
density of 1.5 ×106 cells per well. Cells were transfected
using 1 μg of TAFI-pcDNA4A expression plasmids and
Mega Tran 1.0 (OriGene) according to manufacturer’s
protocol. Stably-expressing cell lines were selected by
culturing in the presence of 100 μg/mL zeocin (Invitro-
gen). Stable cell lines were grown in roller bottle culture
for the production of recombinant TAFI in OptiMEM
(Gibco) supplemented with 1 % antibiotic/antimycotic.
Recombinant TAFI (rTAFI) was purified using a Ni2+
Sepharose column (GE Healthcare Life Sciences), utiliz-
ing the His6-tag at the carboxyl-terminal of the protein.
Conditioned medium harvested from the cells was sup-
plemented with 50 mM NaH2PO4, 0.5 M NaCl, 1 mM
β-ME 10 % glycerol, pH 7.9 (buffer A), containing 5 mM
imidazole. The column was washed and eluted with
wash and elution buffers, which were buffer A contain-
ing 10 mM and 400 mM imidazole, respectively. Eluted
rTAFI was dialyzed overnight at 4 °C against HBS
(0.02 M HEPES pH 7.4, 0.15 M NaCl) containing 5 %
glycerol. Dialyzed rTAFI was then concentrated by ultra-
centrifugation using Amicon Ultra Centrifugal Filters
(Fisher Scientific) at 4 °C with a buffer exchange using
HBS containing 0.01 % (v/v) Tween-80 (HBST).
RNA extraction and quantitative real-time PCR
RNA was extracted from various cell lines using RNeasy
Plus Mini Kit (Qiagen), as per the manufacturer’s proto-
col. Quantitative real-time PCR (qRT-PCR) was com-
pleted using iTaq one-step RT-PCR kit with SYBR®
green (BioRad). The following primers were used for
qRT-PCR: TM sense: 5′ CCC TGA ACA AGA ATT
GGA AGC T 3′; TM antisense: 5′ GGA GCC TAG
GAT TCT GCA TTT CTA 3′; TAFI sense: 5′ GCT
GCC GGA GCG TTA CAT 3′; TAFI antisense: 5′ CAT
TCC TAA TGA CAT GCC AAG CT 3′; GAPDH sense:
5′ GGA GCC AAA AGG GTC ATC ATC 3′; GAPDH
antisense: 5′ GTT CAC ACC CAT GAC GAA CAT
G 3′.
Plasminogen activation assays
Plasminogen activation assays were performed as previ-
ously described by Romagnuolo et al. [22]. Briefly,
MDA-MB-231 and SUM149 cells were grown to con-
fluency in black, clear-bottom 96 well plates. Various
TAFI concentrations were activated in Hank’s buffer sa-
line solution (HBSS) (0.137 M NaCl, 5.4 mM KCl,
0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2,
1 mM MgSO4, 4.2 mM NaHCO3, 1 g/L glucose and
0.1 % BSA) with 25 nM thrombin, 100 nM TM, and
5 mM CaCl2 for 10 min at room temperature. Following
the 10-min incubation, thrombin was inhibited with
PPAck. Cells were washed twice with HBSS. Activated
TAFI (1–50 nM, final) was added to cells for 30 min at
37 °C. Cells were then washed twice with HBSS and a
solution containing 300 nM plasminogen (purified from
human plasma by lysine-sepharose affinity chromatog-
raphy as previously described [23]), 10 pM uPA (Calbio-
chem) and 40 mM of the fluorogenic plasmin substrate
H-D-Val-Leu-Lys-AMC (Bachem). Hydrolysis of H-D-
Val-Leu-Lys-AMC was monitored for an hour at 37 °C
at excitation and emission wavelengths of 370 and
470 nm, respectively.
Cell invasion and migration assays
Cell culture inserts (BD Biosciences) with a pore size of
8 μm were coated with 2 mg/mL Cultrex reconstituted
basement membrane extract (Trevigen) for 1 h at room
temperature. MDA-MB-231 and SUM149 cells (1 × 105)
in serum-free medium were seeded into the upper
chamber. Complete medium was added to the lower
chamber with either 10 ug/mL potato tuber carboxypep-
tidase inhibitor (PTCI) (Sigma) or 10 nM rabbit TM
(Haemotologic Technologies). Cells were allowed to in-
vade for 24 h at 37 °C. Following 24 h, non-invaded cells
in the upper chamber were removed. Invaded cells were
fixed with cold methanol and stained with 0.25 % crystal
violet. Images were taken of five fields of view with a
20× objective and cell numbers in each field were deter-
mined by counting.
For TAFIa treatment, recombinant TAFI was activated
with 25 nM thrombin (Haematologic Technologies), 100
nM TM, and 5 mM CaCl2 for 10 min at room
temperature. Thrombin was inhibited with 200 nM H-D-
Phe-Pro-Arg chloromethylketone (PPAck; Calbiochem)
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and placed on wet ice. The activation mixture was supple-
mented with DMEM containing 10 % FBS and 1 % anti-
biotic and added to the lower chamber to achieve final
TAFIa concentrations of 1, 5, 25, or 50 nM. Mock activa-
tions of rTAFI were carried out in the same manner but
without thrombin.
Cell migration assays were performed using the same
protocol as cell invasion assays, except that the cell cul-
ture inserts were not coated with Cultrex and the cells
were seeded in the upper chamber at a lower density
(3 × 104 cells/well).
Cell metabolism assay
MDA-MB-231 and SUM149 cells (2.5 × 103/well) were
seeded into a 96 well plate. Cells were grown for 24 h.
PTCI or TM was then added to the cells in fresh
medium for 24 h. Following the 24 h, WST-1 reagent
(Roche) was added and incubated for 2 h at 37°C. The
absorbance was then measured at 450 nm using a plate-
reading spectrophotometer.
Live-cell proteolysis assay
Live-cell proteolysis experiments were carried out as de-
scribed by Victor et al. [24]. Round glass-bottom dishes
(MatTek) were coated with Cultrex containing 25 μg/
mL dye quenched (DQ)-collagen IV (Invitrogen). MDA-
MB-231 cells and SUM149 cells were labeled with Cell-
Tracker Orange (Invitrogen) in serum-free medium for
1 h. Cells were allowed to recover in complete medium
before 2 × 104 (SUM149) or 1 × 104 cells (MDA-MB-
231) were seeded onto the Cultrex-coated glass. Dishes
were then incubated at 37 °C for 45 min. Following the
incubation, complete growth medium containing 2 %
Cultrex was added to the cells, with or without 10 μg/
mL PTCI. Cells were incubated at 37 °C and 5 % CO2
for 48 h. Following incubation, cells were imaged using
an Olympus IX81 confocal microscope.
For TAFIa treatment, activated (50 nM) and mock-
activated (50 nM) rTAFI mixtures were prepared as de-
scribed above. Glass-bottom dishes were prepared and
cells were seeded as described above. Each plate was
supplemented with 2 mL of DMEM medium containing
10 % FBS, 1 % antibiotic, 2 % Cultrex and the activation
mixture with or without activated TAFI. Cells were incu-
bated at 37°C and 5 % CO2 for 48 h.
Quantitative analysis of the confocal microscopy data
was performed using the following protocol. Each of the
images (15–20 depending on the size of the spheroid) of
the z-stack in the experiment was initially in TIFF RGB
format, which were then converted to 8-bit grayscale
prior to processing. The images were then filtered to re-
move granulation using a median filter. The brightness
curves were trimmed so that areas of high intensity did
not discard other areas of interest when thresholding;
the identical trimming method was conducted for each
image. Each image was then filtered and tuned (again
using the same parameters in each case), a threshold
based on Otsu’s technique [25] was applied to the image
which converts it to a binary format. The resultant
image contains an accurate depiction of the shape and
contour of the areas of interest. At this stage, the areas
of each image were then calculated by matrix summa-
tion. The average intensity of an image was then deter-
mined by applying the binary image as a mask to the
original grayscale image and calculating the mean pixel
intensity of the resulting matrix. Each pixel is repre-
sented as an 8-bit grayscale value and therefore repre-
sented as a number between 0 and 255. This algorithm
was applied to each image in the same exact manner
without any modifications. The data were represented as
a ratio of the intensity of the green fluorescence to the
area of the cells, averaged over the z-stack.
Statistical analysis
Data from the experiments were presented as means
of at least 3 independent experiments ± standard error
of the mean (SEM). Analysis of the data to identify
statistically significant differences amongst experimen-
tal conditions was completed using one-way ANOVA
with SPSS software (version 22); pairwise comparisons
between conditions were performed using a Tukey
post-hoc analysis. p values <0.05 were considered sta-
tistically significant.
Results
TAFI and TM are expressed in breast cancer cell lines
Expression of CPB2 (the gene encoding TAFI) was
assessed in various breast cancer cell lines, using qRT-
PCR (Fig. 1). CPB2 mRNA was detectable in all of the
examined breast cancer cell lines, albeit at a lower level
in all cases compared to the positive control THP-1
macrophages (Fig. 1), which is correspondingly much
lower than reported in liver or a cultured hepatoma cell
line [11]. CPB2 mRNA levels in the highly malignant
and invasive MDA-MB-231, HTB-126, and MCF10A-
CA1a cell lines were comparable to mRNA levels in the
non-invasive [26] MCF7 cell line. Therefore, levels of
CPB2 mRNA do not appear to show any relationship to
the malignancy of the breast cancer cell lines.
It has been reported that TM expression is inversed
correlated with malignancy in prostate, breast and
lung cancer [20, 27–29]. In contrast to CPB2, the ex-
pression levels of THBD (the gene encoding TM)
were found to be generally inversely correlated to ma-
lignancy (Fig. 1). This relationship is revealed when
the cell lines are arranged in decreasing order of
THBD expression from left to right, as the more ma-
lignant cell lines are on the right.
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TAFIa inhibits plasminogen activation on both MDA-MB-
231 and SUM149 cell lines
Addition of TAFIa resulted in a decrease in plas-
minogen activation of up to 30 % in both MDA-MB-
231 and SUM149 cells (Fig. 2). This decrease, how-
ever, was not strictly dose-dependent, as the magni-
tude of the effect tended to decrease at the highest
concentrations of TAFIa. The ability of TAFIa to de-
crease cell surface plasminogen activation is consist-
ent with its ability to decrease extracellular collagen
proteolysis.
TAFIa directly inhibits cell invasion and migration of
MDA-MB-231 and SUM149 cell lines
We examined the effect of TAFIa on cell invasion of
MDA-MB-231 and SUM149 cell lines by inhibition of
TAFIa using the specific competitive inhibitor PTCI.
Both cell lines should be sensitive to the effects of PTCI
as they both express TM and therefore presumably have
the capacity to support TAFI activation. Inhibition of
TAFIa using 10 μg/mL PTCI resulted in a significant in-
crease in invasion (Fig. 3a, b) and migration (Fig. 4a, b)
of both MDA-MB-231 and SUM149 cells. In addition,
treatment with 10 nM of the cofactor TM resulted in an
approximately 30 % decrease in invasion in both
SUM149 and MDA-MB-231 cell lines (Fig. 3a, b) as well
as decreases in migration of MDA-MB-231 and
SUM149 cells by 30 and 20 %, respectively (Fig. 4a, b).
These results indicate that modulation of TAFI activity
can affect invasion and migration potential of breast
cancer cells.
To directly assess the effect of TAFIa on cell invasion we
used wild-type TAFI (TAFI-WT) as well as a stable variant
(TAFI-CIIYQ) (Fig. 3c, d). While treatment with activated
TAFI-WT (TAFIa-WT) did not affect cell invasion, we ob-
served a dose-dependent decrease in MDA-MB-231 cell in-
vasion upon treatment with TAFIa-CIIYQ. The highest
dose of TAFIa-CIIYQ (50 nM) resulted in an approximately
60 % decrease in invasion of MDA-MB-231 cells (Fig. 3c,
d). Notably, this effect was only observed with the TAFIa
enzyme and not the (non-activated) TAFI zymogen. In
addition, we assessed the effect of TAFI and TAFIa on cell
migration. We observed a dose-dependent decrease in cell
migration of MDA-MB-231 cells when treated with either
TAFIa-WT or TAFIa-CIIYQ (Fig. 4c, d), although signifi-
cance was only reached at 50 nM TAFIa-CIIYQ.
Fig. 1 Expression of CPB2 (TAFI) and THBD (thrombomodulin) mRNA in breast cancer cell lines. RNA was extracted from various breast cancer cell
lines and expression of CPB2 and THBD was analyzed using qRT-PCR. Expression of CPB2 and THBD were normalized to GAPDH mRNA levels in all
cells. The data are expressed relative to THP-1 macrophages (CPB2) or HUVECs (THBD) and are the means ± SEM of 3–4 independent experiments,
and are arranged in decreasing order of THBD expression from left to right. *: p <0.05 versus MCF10A (CPB2) and †: p <0.05 versus
MCF10A (THBD)
Fig. 2 TAFIa inhibits pericellular plasminogen activation on breast
cancer cell lines. SUM149 (black bars) and MDA-MB-231 cells (grey bars)
were treated with varying concentrations of TAFIa (1–50 nM) for
30 min at 37 °C. Plasminogen activation assay was carried out with 300
nM plasminogen, 10 pM uPA and a fluorescent plasmin substrate. The
rate of formation of plasmin (taken as the slope of the plot of change
in fluorescence versus time squared) was monitored for 1 h at 37 °C.
The data represent the means ± SEM of 4–5 independent experiments
and are expressed relative to the control in the absence of TAFIa. **:
p <0.01 relative to control
Bazzi et al. BMC Cancer  (2016) 16:328 Page 5 of 12
Fig. 3 The effects of PTCI, TM and TAFIa on breast cancer cell invasion. a SUM149 and MDA-MB-231 cells were subjected to invasion assays in the
presence of 10 μg/mL PTCI or 10 nM TM or in the absence of these additions (Control). The number of invaded cells were imaged and counted in five
fields of view. Images shown were taken at 4× magnification. Scale bars: 200 μm. b Quantification of invaded cells, relative to control (absence of
treatment). The data represent the average cell number per field of view ± SEM from at least 4 independent experiments. *: p <0.05 and **: p <0.01 relative
to control. c Cells were treated with varying concentrations (1–50 nM) of either TAFIa-WT or TAFIa-CIIYQ or 50 nM mock-activated TAFI-WT or TAFI-CIIYQ
(Non-Activated) for 24 h. Invasion was imaged as in (a). d Quantification of invaded cells, relative to control (absence of TAFIa). The data represent the
average cell number per field of view ± SEM from at least 3 independent experiments. *: p <0.05 and **: p <0.01 relative to control; #: p <0.05 and ## p
<0.01 relative to TAFIa-WT. e To demonstrate the purity of the recombinant TAFI proteins, TAFI-WT and TAFI-CIIYQ (500 ng each) was subjected to
SDS-PAGE on a 12 % polyacrylamide gel followed by staining with silver. The positions of migration of molecular weight markers are shown to the left of
the gel
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Treatment with the non-activated TAFI did not have
an effect on migration, as we observed with cell inva-
sion. These results demonstrate directly that TAFIa
can inhibit breast cancer cell invasion and migration
in vitro.
TAFIa does not affect breast cancer cell proliferation
We next wanted to determine whether manipulation of
TAFI impacted cell proliferation. Treatment with 10 μg/
mL PTCI had no effect while treatment with 10 nM TM
slightly decreased cell proliferation (as measured by a
Fig. 4 The effects of PTCI, TM and TAFIa on breast cancer cell migration. a SUM149 and MDA-MB-231 cells were subjected to migration assays in the
presence of 10 μg/mL PTCI or 10 nM TM or in the absence of these additions (Control). The number of migrated cells were imaged and counted in
five fields of view. Images shown were taken at 4× magnification. Scale bars: 200 μm. b Quantification of migrated cells, relative to control (absence of
treatment). The data represent the average cell number per field of view ± SEM from at least 4 independent experiments. *: p <0.05 and **: p <0.01
relative to control. c Cells were treated with varying concentrations of either TAFIa-WT or TAFIa-CIIYQ (1–50 nM) for 24 h. Cells were also treated with
50 nM mock-activated TAFI-WT or TAFI-CIIYQ (Non-Activated). Migration was imaged as in (a). d Quantification of migrated cells, relative to control in
the absence of TAFIa. The data represent the average cell number per field of view ± SEM from at least three independent experiments. *: p <0.05
relative to control; #: p <0.05 relative to TAFIa-WT
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metabolic assay), albeit to an extent that was not statisti-
cally significant (Fig. 5). This result is in keeping with
previous study conducted in melanoma cells [30]. As
shown in Fig. 5b, treatment of MDA-MB-231 cells with
both variants of TAFI resulted in a slight, albeit again
non-significant, decrease in cell proliferation. This result
was independent of TAFI activation, as addition of
TAFIa gave the same result as addition of the zymogen.
TAFIa inhibits DQ-collagen type IV proteolysis by MDA-
MB-231 and SUM149 cells
We examined the effect of TAFIa on degradation of
DQ-collagen type IV by MDA-MB-231 and SUM149
cells. Inhibition of TAFIa using 10 μg/mL PTCI resulted
in a significant increase in collagen IV proteolysis by
both MDA-MB-231 and SUM149 cells (Fig. 6a-c). DQ-
collagen degradation products were localized both intra-
cellularly (represented by the yellow in the merged im-
ages) and extracellularly.
Next, we sought to directly investigate the effect of
TAFIa on DQ-collagen type IV degradation. MDA-MB-
231 cells were treated with either activated or mock-
activated TAFI variants, TAFI-WT or TAFI-CIIYQ
(Fig. 6d). Intriguingly, addition of TAFI-CIIYQ resulted
in a decrease in collagen type IV proteolysis of approxi-
mately 30 %, irrespective of whether this variant was acti-
vated or not (Fig. 6e). Addition of wild-type TAFI or
TAFIa had no significant effect on proteolysis.
Taken together, these results demonstrate a role for
TAFIa in preventing collagen degradation.
Discussion
TM has been shown to be an anti-metastatic factor in ani-
mal studies [19, 31] and low levels of tumor TM have
been shown to be a negative prognostic indicator in breast
cancer [20]. The anti-metastatic function of TM has been
shown to reside in its ability to bind to thrombin [19]. We
report here that a molecular target of the thrombin TM
complex – namely, TAFI – can inhibit pro-metastatic be-
haviours of breast cancer cells in vitro including invasion,
migration, and extracellular proteolysis.
The thrombin-TM complex activates TAFI over 1000-
fold more efficiently than thrombin alone, and 20-fold
more efficiently than plasmin [32]. Accordingly, we
would hypothesize thrombin-TM to be a relevant activa-
tor of TAFI in the tumor microenvironment, particularly
in the absence of a strong thrombogenic stimulus that
would result in generation of large amounts of thrombin
and plasmin. We found that the more malignant cell
lines tended to express less mRNA encoding TM (Fig. 1),
and hence these cells would be less able to support TAFI
activation. In other words, the more malignant cell lines
are characterized by a relatively low capacity to generate
potentially anti-metastatic TAFIa. Indeed, although Rei-
jerkerk and coworkers found that absence of TAFI did
not affect the growth and metastasis of B16 melanoma
or Lewis lung carcinoma cell lines in mice, these cell
lines are unable to support TAFI activation [33].
Although we were able to detect expression of mRNA
encoding TAFI in breast cancer cells, there was no ap-
parent correlation with malignancy (Fig. 1). This obser-
vation evokes the concept that the limiting factor in the
anti-metastatic TAFI pathway may not be TAFI itself,
but instead the presence of TM that is required for TAFI
activation in this milieu. Indeed, several studies have
shown that plasma TAFI concentrations are elevated in
breast cancer patients and are positively correlated with
endpoints such as poor prognosis and risk of recurrence
[34–36]. These findings are the opposite of what would
be expected given the ability of TAFIa to inhibit pro-
metastatic behaviours such as invasion that we have doc-
umented in this study. Moreover, a common single nu-
cleotide polymorphism in CPB2 encoding a more stable
TAFIa species was also more frequent in breast cancer
patients than controls [35, 36]. In the breast cancer
microenvironment, TM may be provided by the breast
Fig. 5 The effects of PTCI and TM on cell proliferation of breast cancer
cell lines. MDA-MB-231 and SUM149 cells were subjected to the WST-1
assay as an index of proliferation. a Cells were treated with 10 μg/mL
PTCI or 10 nM TM, for 24 h. b MDA-MB-231 cells were treated with 50
nM of the indicated TAFI variants, either with (Activated) or without
(Non-Activated) prior treatment with thrombin-TM. Following the
treatment, the WST-1 assay was conducted and metabolic activity of the
cells assessed by measuring absorbance at 450 nm. The data represent
the average cell number per field of view± SEM from at least three
independent experiments and are relative to the control in the absence
of treatment
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cancer cells and/or by stromal cells such as endothelial
cells and macrophages [37]. TAFI may arise from tumor
cells or macrophages, but more likely from blood plasma
present due to leaky tumor microvasculature [38].
We showed that TAFI can inhibit plasminogen activa-
tion on the breast cancer cell surface (Fig. 2). Carboxyl-
terminal lysine binding sites on cell surface receptors
play a crucial role in plasminogen activation [39]. TAFIa
cleaves carboxyl-terminal lysine residues from various
protein and peptide substrates. Plasmin has a series of
pro-metastatic effects including direct proteolysis of
ECM and basement membrane proteins, activation of la-
tent pro-MMPs, and liberation of latent growth factors
from the extracellular matrix [40]. The decrease in plas-
min generation in the presence of TAFIa likely results in
decreased activation of latent MMPs in the extracellular
milieu, amplifying the effect of TAFIa. It is notable that
inhibition of TAFIa had a greater effect on cell invasion
than cell migration (Figs. 3 and 4). The former requires
cells to degrade the matrix while the latter does not, and
is an index merely of how fast cells can move. While the
PAS has been shown to be important for cell movement
[40], our data suggest a key role for TAFI in blocking
proteolysis of collagen and other extracellular matrix
components.
TAFIa activity is regulated by the intrinsic instability of
the enzyme. While the TAFI zymogen is stable, the en-
zyme undergoes a spontaneous conformational change
that causes loss of activity [21, 41]. The half-life of TAFIa
at body temperature is 8–15 min [42]. When we added
purified recombinant TAFIa to our invasion assays, we
saw no effect (Fig. 3). This is not surprising as the invasion
assay is conducted over 24 h and most of the TAFIa activ-
ity would have disappeared within the first hour. Indeed,
when we used a stable TAFIa variant (TAFIa-CIIYQ) with
a much longer half-life (1140 min [43]) we did observe a
dose-dependent decrease in cell invasion (Fig. 3). Addition
of the non-activated forms of wild-type TAFI or TAFI-
CIIYQ had no effect on invasion (Fig. 3), indicating that
TAFI zymogen concentration was not a limiting factor
under these conditions. However, in cell migration assays,
both enzymes appeared to have an effect (Fig. 4), although
the decreases caused by wild-type TAFIa were non-
significant. Again, addition of the zymogens had no effect
(Fig. 4). The migration assays may have been influenced at
an early stage by the presence of TAFIa, for example if
most of the migration occurred in the first hours of the
24-hour incubation. Assays of the metabolic activity of the
breast cancer cell lines showed minimal impact of ma-
nipulation of TAFIa activity (Fig. 5). These findings sug-
gest that the effect of TAFIa on invasion and migration
can not be attributed to changes in cell proliferation.
Inhibition of TAFIa enhanced DQ-collagen degrad-
ation, indicating an important role for TAFIa in mediat-
ing collagen proteolysis (Fig. 6). Unlike cell migration, in
the proteolysis assays both the wild-type and mutant zy-
mogens of TAFI along with their active counterparts re-
sulted in a decrease in collagen degradation (Fig. 6). The
48-hour incubation for the proteolysis assays may have
allowed for ongoing activation of the added TAFI to
have manifested in less accumulation of degraded DQ-
collagen type IV. In the breast tumor microenvironment,
we would expect continuous activation of TAFI through
the action on small amounts of thrombin generated in
situ interacting with TM on the surface of different cell
types in this environment. We observed the presence of
DQ-collagen type IV proteolysis both extracellularly and
intracellularly (Fig. 6). The proteases and pathways in-
volved in pericellular proteolysis versus intracellular pro-
teolysis are distinct [44, 45]. Pericellular proteolysis
involves MMPs, serine proteases (including components
of the plasminogen activation system), and cysteine pro-
teases [44, 45]. Intracellular proteolysis involves endo-
cytosis of DQ-collagen IV by the live cells followed by
degradation of the substrate in the lysosome [45–47].
Intracellular proteolysis can also occur after partial
degradation of DQ-collagen type IV by pericellular
proteases with subsequent endocytosis and further
degradation in the lysosome [48]. As such, an in-
crease in intracellular proteolysis also reflects the ex-
tent of pericellular proteolysis. We saw effects of
manipulation of TAFIa activity on both pericellular
and intracellular proteolysis (Fig. 6), but since TAFIa
acts outside the cell, we would argue that TAFIa dir-
ectly affects pericellular proteolysis, with an indirect
effect on intracellular proteolysis.
(See figure on previous page.)
Fig. 6 Inhibition of TAFIa increases proteolysis of DQ-collagen type IV by breast cancer cells. SUM149 (a) and MDA-MB-231 (b) cells labeled with
CellTracker Orange (shown in red) were grown on reconstituted basement membrane extract containing 25 μg/mL DQ-collagen IV. Cells were
treated with 10 μg/mL PTCI for 48 h. Confocal images were taken following the 48 h treatment. DQ-collagen degradation products were
observed in green. Scale bars: 20 μm. c DQ-collagen fluorescence was quantified and normalized to the area of CellTracker Orange fluorescence.
The data are represented as the green fluorescent intensity per area of the red fluorescence, averaged across the entire z-stack and expressed
relative to untreated cells (Control). The data represent the mean ± SEM of three independent experiments, each carried out in triplicate. *: p
<0.05 versus Control. d MDA-MB-231 cells labeled with CellTracker Orange (shown in red) were grown on rBM containing 25 μg/mL DQ-collagen
IV and treated with 50 nM of either TAFIa-WT or TAFIa-CIIYQ, or with 50 nM mock-activated TAFI-WT or TAFI-CIIYQ. Confocal images of cells (red)
and DQ-collagen IV degradation products (green) were captured after 48 h. Scale bars: 20 μm. e Degradation of DQ-collagen IV was quantified as
in (c). The data represent the mean ± SEM of three independent experiments, each carried out in triplicate. *: p <0.05 versus Control
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Conclusions
In conclusion, we have demonstrated for the first
time that activation of TAFI results in a suppression
of breast cancer cell invasion and migration. Our data
are consistent with the idea that TAFIa mediates
these effects by inhibiting pericellular plasminogen ac-
tivation and by attenuating proteolysis of collagen
type IV. Further work will be required to define the
full spectrum of the effects of TAFIa on specific pro-
teases and protease targets in the breast tumour
microenvironment. Our results indicate that promo-
tion of TAFI activation in this microenvironment, ei-
ther by provision of soluble TM or stabilization of
TAFIa, would have anti-metastatic effects.
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